A novel treatment strategy for sepsis and septic shock based on the interactions between prostanoids, Nitric Oxide, and 20-Hydroxyeicosatetraenoic acid

Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry

Volumn 11, Issue 2, 2012, Pages 121-150

  Tunctan, Bahar ^a   Korkmaz, Belma ^a   Sari, Ayse Nihal ^a   Kacan, Meltem ^a   Unsal, Demet ^a   Serin, Mehmet Sami ^a   Buharalioglu, C Kemal ^a   Sahan Firat, Seyhan ^a   Schunck, Wolf Hagen ^b   Falck, John R ^c   Malik, Kafait U ^d  

^a MERSIN UNIVERSITY   (Turkey)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

20 HETE; COX 2; CYP4A; iNOS; Sepsis; Septic shock

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; ACETYLSALICYLIC ACID; AMPHOTERICIN B; ANTIBIOTIC AGENT; CEPHALOSPORIN; CORTICOSTEROID; CYTOCHROME P450 4A1; GLUCOSE; HYDROCORTISONE; HYPERTENSIVE FACTOR; IBUPROFEN; INSULIN; LORNOXICAM; MACROLIDE; MESSENGER RNA; N (G) METHYLARGININE; N (G) NITROARGININE; N (G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PLACEBO; PROSTAGLANDIN; PROSTANOID; QUINOLONE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANEMIA; ANTIMICROBIAL THERAPY; BLOOD GLUCOSE MONITORING; CLINICAL ASSESSMENT; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG SYNTHESIS; ENDOTOXEMIA; HUMAN; HYPERGLYCEMIA; METABOLIC ACIDOSIS; MORTALITY; MULTICENTER STUDY (TOPIC); MULTIPLE ORGAN FAILURE; NONHUMAN; NUTRITION; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRESSORECEPTOR REFLEX; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOGNITION; RECOMMENDED DRUG DOSE; REVIEW; SEPSIS; SEPTIC SHOCK;

ANIMALS; CYCLOOXYGENASE INHIBITORS; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROSTAGLANDINS; SEPSIS; SHOCK, SEPTIC;

EID: 84870270905     PISSN: 18715230     EISSN: 1875614X     Source Type: Journal    
DOI: 10.2174/187152312803305759     Document Type: Review

References (264)

1. Carney, D.E.; Matsushima, K.; Frankel, H.L. Treatment of sepsis in the surgical intensive care unit. Isr. Med. Assoc. J., 2011, 13(11), 694-699.
2. Cauwels, A. Nitric oxide in shock. Kidney Int., 2007, 72(5), 557-565.
3. Cohen, J. Non-antibiotic strategies for sepsis. Clin. Microbiol. Infect., 2009, 15(4), 302-307.
4. Dyson, A.; Singer, M. Animal models of sepsis: Why does preclinical efficacy fail to translate to the clinical setting? Crit. Care Med., 2009, 37(1 Suppl), S30-S37.
5. Gustot, T. Multiple organ failure in sepsis: Prognosis and role of systemic inflammatory response. Curr. Opin. Crit. Care, 2011, 17(2), 153-159.
6. Latto, C. An overview of sepsis. Dimens. Crit. Care Nurs., 2008, 27(5), 195-200.
7. Martin, J.B.; Wheeler, A.P. Approach to the patient with sepsis. Clin. Chest. Med., 2009, 30(1), 1-16.
8. Morrell, M.R.; Micek, S.T.; Kollef, M.H. The management of severe sepsis and septic shock. Infect. Dis. Clin. North Am., 2009, 23(3), 485-501.
9. Puskarich, M.A. Emergency management of severe sepsis and septic shock. Curr. Opin. Crit. Care, 2012, 18(4), 295-300.
10. Rivers, E.P.; Katranji, M.; Jaehne, K.A.; Brown, S.; Abou Dagher, G.; Cannon, C.; Coba, V. Early interventions in severe sepsis and septic shock: a review of the evidence one decade later. Minerva Anestesiol., 2012, 78(6), 712-724.
11. Silva, E.; Passos Rda, H.; Ferri, M.B.; de Figueiredo, L.F. Sepsis: from bench to bedside. Clinics (Sao Paulo), 2008, 63(1), 109-120.
12. Cavaillon, J.M.; Adib-Conquy, M.; Fitting, C.; Adrie, C.; Payen, D. Scand. Cytokine cascade in sepsis. J. Infect. Dis., 2003, 35(9), 535-544.
13. Angus, D.C.; Linde-Zwirble, W.T.; Lidicker, J.; Clermont, G.; Carcillo, J.; Pinsky, M.R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med., 2001, 29(7), 1303-1310.
14. Bernard, G.R.; Margolis, B.D.; Shanies HM.; Ely EW.; Wheeler AP.; Levy H.; Wong K.; Wright TJ. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): A single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis. Chest, 2004, 125(6), 2206-2216.
15. Martin, G.S.; Mannino, D.M.; Eaton, S.; Moss, M. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med., 2003, 348(16), 1546-1554.
16. Martin, G.S.; Mannino, D.M.; Moss, M. The effect of age on the development and outcome of adult sepsis. Crit. Care Med., 2006, 34(1), 15-21.
17. Alberti, C.; Brun-Buisson, C.; Burchardi, H.; Martin, C.; Goodman, S.; Artigas, A.; Sicignano, A.; Palazzo, M.; Moreno, R.; Boulme, R.; Lepage, E.; Le Gall, R. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med., 2002; 28(2): 108-121.
18. Annane, D.; Bellissant, E.; Cavaillon, J.M. Septic shock. Lancet, 2005, 365(9453), 63-78.
19. Dombrovskiy, V.Y.; Martin, A.A.; Sunderram, J.; Paz, H.L. Occurrence and outcomes of sepsis: Influence of race. Crit. Care Med., 2007, 35(3), 763-768.
20. Lin, M.T.; Albertson, T.E. Genomic polymorphisms in sepsis. Crit. Care Med., 2004, 32(2), 569-579.
21. Rangel-Frausto, M.S.; Pittet, D.; Costigan, M.; Hwang, T.; Davis, C.S.; Wenzel, R.P. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA, 1995, 273(2), 117-123.
22. Annane, D., Sebille, V.; Charpentier, C.; Bollaert, P.E.; François, B.; Korach, J.M.; Capellier, G.; Cohen, Y.; Azoulay, E.; Troche, G.; Chaumet-Riffaud, P.; Bellissant, E. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA, 2002, 288(7), 862-871.
23. Gao, H.; Evans, T.W.; Finney, S. Bench-to-bedside review: sepsis, severe sepsis and septic shock -does the nature of the infecting organism matter? J. Crit. Care, 2008, 12(3), 213.
24. Nduka, O.O.; Parrillo, J.E. The pathophysiology of septic shock. Crit. Care Nurs. Clin. North Am., 2011, 23(1), 41-66.
25. Opal, S.M. Endotoxins and other sepsis triggers. Contrib. Nephrol., 2010, 167, 14-24.
26. Kellum, J.A.; Kong, L.; Fink, M.P.; Weissfeld, L.A.; Yealy, D.M.; Pinsky, M.R.; Fine, J.; Krichevsky, A.; Delude, R.L.; Angus, D.C; GenIMS Investigators. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch. Intern. Med., 2007, 167(15), 1655-1663.
27. Levy, B.; Collin, S.; Sennoun, N.; Ducrocq, N.; Kimmoun, A.; Asfar, P.; Perez, P.; Meziani, F. Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside. Intensive Care Med., 2010, 36(12), 2019-2029.
28. Rudiger, A.; Stotz, M.; Singer, M. Cellular processes in sepsis. Swiss Med. Wkly., 2008, 138(43-44), 629-634.
29. Janeway, C.A.Jr.; Medzhitov, R. Introduction: The role of innate immunity in the adaptive immune response. Semin. Immuno., 1998, 10(5), 349-350.
30. Bernard, G.R.; Vincent, J.L.; Laterre, P.F.; LaRosa, S.P.; Dhainaut, J.F.; Lopez-Rodriguez, A.; Steingrub, J.S.; Garber, G.E.; Helterbrand, J.D.; Ely, E.W.; Fisher, C.J. Jr; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med., 2001, 344(10), 699-709.
31. Seydel, U.; Oikawa, M.; Fukase, K.; Kusumoto, S.; Brandenburg, K. Intrinsic conformation of lipid A is responsible for agonistic and antagonistic activity. Eur. J. Biochem., 2000, 267(10), 3032-3039.
32. Majcherczyk, P.A.; Langen, H.; Heumann, D.; Fountoulakis, M.; Glauser, M.P.; Moreillon, P. Digestion of Streptococcus pneumoniae cell walls with its major peptidoglycan hydrolase releases branched stem peptides carrying proinflammatory activity. Biol. Chem., 1999, 274(18), 12537-12543.
33. Inagawa, H.; Kohchi, C.; Soma, G. Oral administration of lipopolysaccharides for the prevention of various diseases: Benefit and usefulness. Anticancer Res., 2011, 31(7), 2431-2436.
34. Raetz, C.R.; Guan, Z.; Ingram, B.O.; Six, D.A.; Song, F.; Wang, X.; Zhao, J. Discovery of new biosynthetic pathways: the lipid A story. J. Lipid Res., 2009, 50, S103-S108.
35. Martins, P.S.; Brunialti, M.K.; da Luz Fernandes, M.; Martos, L.S.; Gomes, N.E.; Rigato, O.; Salomao, R. Bacterial recognition and induced cell activation in sepsis. Endocr. Metab. Immune Disord. Drug Targets, 2006, 6(2), 183-191.
36. Wittebole, X.; Castanares-Zapatero, D.; Laterre, P.F. Toll-like receptor 4 modulation as a strategy to treat sepsis. Mediators Inflamm., 2010, 2010, 568396.
37. Brown, J.; Wang, H.; Hajishengallis, G.N.; Martin, M. TLRsignaling networks: An integration of adaptor molecules, kinases, and cross-talk. J. Dent. Res., 2011, 90(4), 417-427.
38. Lu, Y.C.; Yeh, W.C.; Ohashi, P.S. LPS/TLR4 signal transduction pathway. Cytokine, 2008, 42(2), 145-151.
39. Pawar, R.D.; Patole, P.S.; Wörnle, M.; Anders, H.J. Microbial nucleic acids pay a Toll in kidney disease. Am. J. Physiol. Renal Physiol., 2006, 291(3), F509-F516.
40. Brower, R.G.; Lanken, P.N.; MacIntyre, N.; Matthay, M.A.; Morris, A.; Ancukiewicz, M.; Schoenfeld, D.; Thompson, BT.; National Heart, Lung, and Blood Institute ARDS Clinical Trials Network. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N. Engl. J. Med., 2004, 351(4), 327-336.
41. Cullen, J.J.; Titler, S.; Ephgrave, K.S.; Hinkhouse, M.M. Gastric emptying of liquids and postprandial pancreatobiliary secretion are temporarily impaired during endotoxemia. Dig. Dis. Sci., 1999, 44(11), 2172-2177.
42. Strassburg, C.P. Gastrointestinal disorders of the critically ill. Shock liver. Best Pract. Res. Clin. Gastroenterol., 2003, 17(3), 369-381.
43. Johnston, J.D.; Harvey, C.J.; Menzies, I.S.; Treacher, D.F. Gastrointestinal permeability and absorptive capacity in sepsis. Crit. Care Med., 1996, 24(7), 1144-1149.
44. Mehta, R.L.; Kellum, J.A.; Shah, S.V.; Molitoris, B.A.; Ronco, C.; Warnock, D.G.; Levin, A.; Acute Kidney Injury Network. Acute Kidney Injury Network: Report of an initiative to improve outcomes in acute kidney injury. Crit. Care, 2007, 11(2), R31.
45. Barrantes, F.; Tian, J.; Vazquez, R.; Amoateng-Adjepong, Y.; Manthous, C.A. Acute kidney injury criteria predict outcomes of critically ill patients. Crit. Care Med., 2008, 36(5), 1397-1403.
46. May, C.N.; Calzavacca, P.; Ishikawa, K.; Langenberg, C.; Wan, L.; Ramchandra, R.; Bellomo, R. Novel targets for sepsis induced kidney injury: The glomerular arterioles and the sympathetic nervous system. Exp. Physiol., 2012, Jun 11.
47. Bernard, G.R.; Wheeler, A.P.; Russell, J.A.; Schein, R.; Summer, W.R.; Steinberg, K.P.; Fulkerson, W.J.; Wright, P.E.; Christman, B.W.; Dupont, W.D.; Higgins, S.B.; Swindell, B.B. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N. Engl. J. Med., 1997, 336(13), 912-918.
48. Hotchkiss, R.S.; Swanson, P.E.; Freeman, B.D.; Tinsley, K.W.; Cobb, J.P.; Matuschak, G.M.; Buchman, T.G.; Karl, I.E. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit. Care Med., 1999, 27(7), 1230-1251.
49. Hotchkiss, R.S.; Tinsley, K.W.; Swanson, P.E.; Chang, K.C.; Cobb, J.P.; Buchman, T.G.; Korsmeyer, S.J.; Karl, I.E. Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc. Natl. Acad. Sci. USA. 1999, 96(25), 14541-14546.
50. Hotchkiss, R.S.; Tinsley, K.W.; Swanson, P.E.; Schmieg, R.E.Jr.; Hui, J.J.; Chang, K.C.; Osborne, D.F.; Freeman, B.D.; Cobb, J.P.; Buchman, T.G.; Karl, I.E. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J. Immunol., 2001, 166(11), 6952-6963.
51. Nakagawa, N.K.; Nogueira, R.A.; Correia, C.J.; Shiwa, S.R.; Costa Cruz, J.W.; Poli de Figueiredo, L.F. Leukocyte-endothelium interactions after hemorrhagic shock/reperfusion and cecal ligation/ puncture: An intravital microscopic study in rat mesentery. Shock, 2006, 26(2), 180-186.
52. Döcke, W.D.; Randow, F.; Syrbe, U.; Krausch, D.; Asadullah, K.; Reinke, P.; Volk, HD.; Kox, W. Monocyte deactivation in septic patients: Restoration by IFN-gamma treatment. Nat. Med., 1997, 3(6), 678-681.
53. Levy, M.M.; Macias, W.L.; Vincent, J.L.; Russell, J.A.; Silva, E.; Trzaskoma, B.; Williams, M.D. Early changes in organ function predict eventual survival in severe sepsis. Crit. Care Med., 2005, 33(10), 2194-2201.
54. Singer, M.; De Santis, V.; Vitale, D.; Jeffcoate, W. Multiorgan failure is an adaptive, endocrine-mediated, metabolic response to overwhelming systemic inflammation. Lancet, 2004, 364(9433), 545-548.
55. Gibot, S.; Cravoisy, A.; Kolopp-Sarda, M.N, Bene, M.C.; Faure, G.; Bollaert, P.E.; Levy, B. Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis. Crit. Care Med., 2005, 33(4), 792-796.
56. Rivers, EP.; Kruse, J.A.; Jacobsen, G.; Shah, K.; Loomba, M.; Otero, R.; Childs, E.W. The influence of early hemodynamic optimization on biomarker patterns of severe sepsis and septic shock. Crit. Care Med., 2007, 35(9), 2016-2024.
57. Shapiro, N.I.; Trzeciak, S.; Hollander, J.E.; Birkhahn, R.; Otero, R.; Osborn, T.M.; Moretti, E.; Nguyen, HB.; Gunnerson, K.J.; Milzman, D.; Gaieski, D.F.; Goyal, M.; Cairns, C.B.; Ngo, L.; Rivers, E.P. A prospective, multicenter derivation of a biomarker panel to assess risk of organ dysfunction, shock, and death in emergency department patients with suspected sepsis. Crit. Care Med., 2009, 37(1), 96-104.
58. Castelli, G.P.; Pognani, C.; Meisner, M.; Stuani, A.; Bellomi, D.; Sgarbi, L. Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction. Crit. Care, 2004, 8(4), R234-R242.
59. Nobre, V.; Harbarth, S.; Graf, J.D.; Rohner, P.; Pugin, J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: A randomized trial. Am. J. Respir. Crit. Care Med., 2008, 177(5), 498-505.
60. Friswell, A.C. Surviving Sepsis Campaign Previews Updated Guidelines for 2012. Pulm. Rev., 2012, 17(5), 1, 5.
61. Wang, J.F.; Yu, M.L.; Yu, G.; Bian, J.J.; Deng, X.M.; Wan, X.J.; Zhu, K.M. Serum miR-146a and miR-223 as potential new bio markers for sepsis. Biochem. Biophys. Res. Commun., 2010, 394(1), 184-188.
62. Vasilescu, C.; Rossi, S.; Shimizu, M.; Tudor, S.; Veronese, A.; Ferracin, M.; Nicoloso, M.S.; Barbarotto, E.; Popa, M.; Stanciulea, O.; Fernandez, M.H.; Tulbure, D.; Bueso-Ramos, C.E.; Negrini, M.; Calin, G.A. MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsis. PLoS One, 2009, 4(10), e7405.
63. Wang, H.; Meng, K.; Chen, W.J.; Feng, D.; Jia, Y.; Xie, L. Serum miR-574-5p: A prognostic predictor of sepsis patients. Shock, 2012, 37(3), 263-267.
64. Lichtenstern, C.; Brenner, T.; Bardenheuer, H.J.; Weigand, M.A. Predictors of survival in sepsis: What is the best inflammatory marker to measure? Curr. Opin. Infect. Dis., 2012, 25(3), 328-36.
65. Ivady, B.; Beres, B.J.; Szabo, D. Recent advances in sepsis research: Novel biomarkers and therapeutic targets. Curr. Med. Chem., 2011, 18(21), 3211-3225.
66. Montano, M. MicroRNAs: miRRORS of health and disease. Transl. Res., 2011, 157(4), 157-162.
67. Vincent, J.L. Clinical sepsis and septic shock-definition, diagnosis and management principles. Langenbecks Arch. Surg., 2008, 393(6), 817-824.
68. De Backer, D. Treatment of shock. Acta Clin. Belg., 2011, 66(6), 438-442.
69. Kanji, Z.; Dumaresque, C. Time to effective antibiotic administration in adult patients with septic shock: A descriptive analysis. Intensive Crit. Care Nurs., 2012, Apr 24.
70. Havel, C.; Arrich, J.; Losert, H.; Gamper, G.; Müllner, M.; Herkner, H. Vasopressors for hypotensive shock. Cochrane Database Syst. Rev., 2011, 11(5), CD003709.
71. Patel, G.P.; Balk, R.A. Systemic steroids in severe sepsis and septic shock. Am. J. Respir. Crit. Care. Med., 2012, 185(2), 133-139.
72. Yarema, T.C.; Yost, S. Low-dose corticosteroids to treat septic shock: A critical literature review. Crit. Care Nurse., 2011, 31(6), 16-26.
73. Dellinger, R.P.; Levy, M.M.; Carlet, J.M.; Bion, J.; Parker, M.M.; Jaeschke, R.; Reinhart, K.; Angus, D.C.; Brun-Buisson, C.; Beale, R.; Calandra, T.; Dhainaut, J.F.; Gerlach, H.; Harvey, M.; Marini, J.J.; Marshall, J.; Ranieri, M.; Ramsay, G.; Sevransky, J.; Thompson, B.T.; Townsend, S.; Vender, J.S.; Zimmerman, J.L.; Vincent, J.L; International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit. Care Med., 2008, 36(1), 296-327.
74. Rivers, E.; Nguyen, B.; Havstad, S.; Ressler, J.; Muzzin, A.; Knoblich, B.; Peterson, E.; Tomlanovich, M. Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N. Engl. J. Med., 2001, 345(19), 1368-1377.
75. Bendjelid, K.; Romand, J.A. Fluid responsiveness in mechanically ventilated patients: A review of indices used in intensive care. Fluid responsiveness in mechanically ventilated patients: A review of indices used in intensive care. Intensive Care Med., 2003, 29(3), 352-360.
76. Finfer, S.; Bellomo, R.; Boyce, N.; French, J.; Myburgh, J.; Norton, R; SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N. Engl. J. Med., 2004, 350(22), 2247-2256.
77. Schortgen, F.; Lacherade, J.C.; Bruneel, F.; Cattaneo, I.; Hemery, F.; Lemaire, F.; Brochard, L. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: A multicentre randomised study. Lancet, 2001, 357(9260), 911-916.
78. De Jonge, E.; Levi, M. Effects of different plasma substitutes on blood coagulation: A comparative review. Crit. Care Med., 2001, 29(6), 1261-1267.
79. Ibrahim, E.H.; Sherman, G.; Ward, S.; Fraser, V.J.; Kollef, M.H. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest, 2000, 118(1), 146-155.
80. Morrell, M.; Fraser, V.J.; Kollef, M.H. Antimicrob. Agents Chemother., 2005, 49(9), 3640-3645.
81. Kollef, M.H.; Sherman, G.; Ward, S.; Fraser, V.J. Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest, 1999, 115(2), 462-474.
82. Kumar, A.; Roberts, D.; Wood, KE.; Light, B.; Parrillo, J.E.; Sharma, S.; Suppes, R.; Feinstein, D.; Zanotti, S.; Taiberg, L.; Gurka, D.; Kumar, A.; Cheang, M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit. Care Med., 2006, 34(6), 1589-1596.
83. Dellit, T.H.; Owens, R.C.; McGowan, J.E.Jr.; Gerding, D.N.; Weinstein, R.A.; Burke, J.P.; Huskins, W.C.; Paterson, D.L.; Fishman, N.O.; Carpenter, C.F.; Brennan, P.J.; Billeter, M.; Hooton, T.M; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin. Infect. Dis., 2007, 44(2),159-77.
84. Micek, S.T.; Roubinian, N.; Heuring, T.; Bode, M.; Williams, J.; Harrison, C.; Murphy, T.; Prentice, D.; Ruoff, B.E.; Kollef, M.H. Before-after study of a standardized hospital order set for the management of septic shock. Crit. Care Med., 2006, 34(11), 2707-2713.
85. Forsythe, S.M.; Schmidt, G.A. Sodium bicarbonate for the treatment of lactic acidosis. Chest, 2000, 117(1), 260-267.
86. LeDoux, D.; Astiz, M.E.; Carpati, C.M.; Rackow, E.C. Effects of perfusion pressure on tissue perfusion in septic shock. Crit. Care Med., 2000, 28(8), 2729-2732.
87. Sprung, C.L.; Annane, D.; Keh, D.; Moreno, R.; Singer, M.; Freivogel, K.; Weiss, Y.G.; Benbenishty, J.; Kalenka, A.; Forst, H.; Laterre, P.F.; Reinhart, K.; Cuthbertson, B.H.; Payen, D.; Briegel, J.; CORTICUS Study Group. Hydrocortisone therapy for patients with septic shock. N. Engl. J. Med., 2008, 358(2), 111-124.
88. Briegel, J.; Forst, H.; Haller, M.; Schelling, G.; Kilger, E.; Kuprat, G.; Hemmer, B.; Hummel, T.; Lenhart, A.; Heyduck, M.; Stoll, C.; Peter, K. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit. Care Med., 1999, 27(4),723-732.
89. Reincke, M.; Allolio, B.; Würth, G.; Winkelmann, W. The hypothalamic-pituitary-adrenal axis in critical illness: Response to dexamethasone and corticotropin-releasing hormone. J. Clin. Endocrinol. Metab., 1993, 77(1), 151-156.
90. Faust, S.N.; Levin, M.; Harrison, O.B.; Goldin, R.D.; Lockhart, M.S.; Kondaveeti, S.; Laszik, Z.; Esmon, C.T.; Heyderman, R.S. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N. Engl. J. Med., 2001, 345(6), 408-416.
91. Riewald, M.; Petrovan, R.J.; Donner, A.; Mueller, B.M.; Ruf, W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science, 2002, 296(5574), 1880-1882.
92. Abraham, E.; Laterre, P.F.; Garg, R.; Levy, H.; Talwar, D.; Trzaskoma, B.L.; François, B.; Guy, J.S.; Brückmann, M.; Rea-Neto, A.; Rossaint, R.; Perrotin, D.; Sablotzki, A.; Arkins, N.; Utterback, B.G.; Macias, W.L.; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N. Engl. J. Med., 2005, 353(13), 1332-1341.
93. Gao, F.; Gao, E.; Yue, T.L.; Ohlstein, E.H.; Lopez, B.L.; Christopher, T.A.; Ma, X.L. Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: The roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation, 2002, 105(12), 1497-1502.
94. van den Berghe, G.; Wouters, P.; Weekers, F.; Verwaest, C.; Bruyninckx, F.; Schetz, M.; Vlasselaers, D.; Ferdinande, P.; Lauwers, P.; Bouillon, R. Intensive insulin therapy in critically ill patients. N. Engl. J. Med., 2001, 345(19), 1359-1367.
95. Brunkhorst, F.M.; Engel, C.; Bloos, F.; Meier-Hellmann, A.; Ragaller, M.; Weiler, N.; Moerer, O.; Gruendling, M.; Oppert, M.; Grond, S.; Olthoff, D.; Jaschinski, U.; John, S.; Rossaint, R.; Welte, T.; Schaefer, M.; Kern, P.; Kuhnt, E.; Kiehntopf, M.; Hartog, C.; Natanson, C.; Loeffler, M.; Reinhart, K; German Competence Network Sepsis (SepNet). Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N. Engl. J. Med., 2008, 358(2), 125-139.
96. Corwin, H.L.; Gettinger, A.; Rodriguez, R.M.; Pearl, R.G.; Gubler, K.D.; Enny, C.; Colton, T.; Corwin, M.J. Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized, double-blind, placebo-controlled trial. Crit. Care Med., 1999, 27(11), 2346-2350.
97. Stacpoole, P.W.; Wright, E.C.; Baumgartner, T.G.; Bersin, R.M.; Buchalter, S.; Curry, S.H.; Duncan, C.A.; Harman, E.M.; Henderson, G.N.; Jenkinson, S.; Lachin, J.M.; Lorenz, A.; Schneider, S.H.; Siegel, J.H.; Summer, W.R.; Thompson, D.; Wolfe, C.L.; Zorovich, B.; the Dichloroacetate-Lactic Acidosis Study Group. A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in adults. The Dichloroacetate-Lactic Acidosis Study Group. N. Engl. J. Med., 1992, 327(22), 1564-1569.
98. Nguyen, N.Q.; Fraser, R.J.; Bryant, L.K.; Chapman, M.; Holloway, R.H. Diminished functional association between proximal and distal gastric motility in critically ill patients. Intensive Care Med., 2008, 34(7), 1246-1255.
99. Marik, P.E.; Zaloga, G.P. Early enteral nutrition in acutely ill patients: A systematic review. Crit. Care Med., 2001, 29(12), 2264-2270.
100. Roberts, S.R.; Kennerly, D.A.; Keane, D.; George, C. Nutrition support in the intensive care unit. Adequacy, timeliness, and outcomes. Crit. Care Nurse., 2003, 23(6), 49-57.
101. Basu, S. Novel cyclooxygenase-catalyzed bioactive prostaglandin F2alpha from physiology to new principles in inflammation. Med. Res. Rev., 2007, 27(4), 435-468.
102. Cook, J.A. Eicosanoids. Crit. Care Med., 2005, 33(12 Suppl), S488-S491.
103. Feletou, M.; Huang, Y.; Vanhoutte, P.M. Endothelium-mediated control of vascular tone: COX-1 and COX-2 products. Br. J. Pharmacol., 2011, 164(3), 894-912.
104. Ricciotti, E.; FitzGerald, G.A. Prostaglandins and inflammation. Arterioscler. Thromb. Vasc. Biol., 2011, 31(5), 986-1000.
105. Kim, S.F. The role of nitric oxide in prostaglandin biology; update. Nitric Oxide, 2011, 25(3), 255-264.
106. Malhotra, S.; Deshmukh, S.S.; Dastidar, S.G. COX inhibitors for airway inflammation. Expert Opin. Ther. Targets, 2012, 16(2), 195-207.
107. Smith, W.L.; Urade, Y.; Jakobsson, P.J. Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. Chem. Rev., 2011, 111(10), 5821-5865.
108. Kalinski, P. Regulation of immune responses by prostaglandin E2. J. Immunol., 2012, 188(1), 21-28.
109. Kawabata, A. Prostaglandin E2 and pain-an update. Biol. Pharm. Bull., 2011, 34(8), 1170-1173.
110. Ashorobi, R.B., Williams, P.A. Indomethacin and alpha-tocopheral enhanced survival in endotoxic rats. Cent. Afr. J. Med., 1995, 41(7), 216-219.
111. Fatehi-Hassanabad, Z.; Muller, M.; Andriantsitohaina, R.; Furman, B.L.; Parratt, J.R.; Stoclet, J.C. Influence of indomethacin on the haemodynamic effects of lipopolysaccharide in rats. Fundam. Clin. Pharmacol., 1996, 10(3), 258-263.
112. Futaki, N.; Takahashi, S.; Kitagawa, T.; Yamakawa, Y.; Tanaka, M.; Higuchi, S. Selective inhibition of cyclooxygenase-2 by NS-398 in endotoxin shock rats in vivo. Inflam. Res., 1997, 46(12), 496-502.
113. Tsiotou, AG.; Sakorafas, G.H.; Anagnostopoulos, G.; Bramis, J. Septic shock; current pathogenetic concepts from a clinical perspective. Med. Sci. Monit., 2005, 11(3), RA76-RA85.
114. Vayssettes-Courchay, C.; Bouysset, F.; Verbeuren, T.J. Involvement of COX and NOS induction in the sympatho-activation during sepsis. Auton. Neurosci., 2002, 98(1-2), 33-36.
115. Aronoff, D.M. Cyclooxygenase inhibition in sepsis: Is there life after death? Mediators Inflamm., 2012, 2012, 696-897.
116. Faist, E.; Ertel, W.; Cohnert, T.; Huber, P.; Inthorn, D.; Heberer, G. Immunoprotective effects of cyclooxygenase inhibition in patients with major surgical trauma. J. Trauma, 1990, 30(1), 8-17.
117. Haupt, M.T.; Jastremski, M.S.; Clemmer, T.P.; Metz, C.A.; Goris, G.B. Effect of ibuprofen in patients with severe sepsis: A randomized, double-blind, multicenter study. The Ibuprofen Study Group. Crit. Care Med., 1991, 19(11), 1339-1347.
118. Arons, M.M.; Wheeler, A.P.; Bernard, G.R.; Christman, B.W.; Russell, J.A.; Schein, R.; Summer, W.R.; Steinberg, K.P.; Fulkerson, W.; Wright, P.; Dupont, W.D.; Swindell, B.B. Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Ibuprofen in Sepsis Study Group. Crit. Care Med., 1999, 27(4), 699-707.
119. Memis, D.; Karamanlioǧlu, B.; Turan, A.; Koyuncu, O.; Pamukçu, Z. Effects of lornoxicam on the physiology of severe sepsis. Crit. Care, 2004, 8(6), R474-R482.
120. Eisen, D.P.; Reid, D., McBryde, E.S. Acetyl salicylic acid usage and mortality in critically ill patients with the systemic inflammatory response syndrome and sepsis. Crit. Care Med., 2012, 40(6), 1761-1767.
121. Alderton, W.K.; Cooper, C.E.; Knowles, R.G. Nitric oxide synthases: Structure, function and inhibition. Biochem. J., 2001, 357(Pt 3), 593-615.
122. Du, Q.; Geller, D.A. In Nitric Oxide: Biology and Pathobiology; Ignarro, L.J., Ed., Elsevier Inc.: California, 2010; pp. 269-300.
123. Förstermann, U. In Nitric Oxide: Biology and Pathobiology; Ignarro, L.J., Ed., Elsevier Inc.: California, 2010; pp. 139-167.
124. Förstermann, U.; Sessa, W.C. Nitric oxide synthases: Regulation and function. Eur. Heart J., 2012, 33(7), 829-837.
125. Kleinert, H.; Art, J.; Pautz, A. In Nitric Oxide: Biology and Pathobiology; Ignarro, L.J., Ed., Elsevier Inc.: California, 2010; pp. 211-267.
126. Luiking, Y.C.; Engelen, M.P.; Deutz, N.E. Regulation of nitric oxide production in health and disease. Curr. Opin. Clin. Nutr. Metab. Care, 2010, 13(1), 97-104.
127. Tunctan, B.; Altug, S. The use of nitric oxide synthase inhibitors in inflammatory diseases: A novel class of anti-inflammatory agents. Cur. Med. Chem. Anti-Inflamm Anti-Allergy Agents, 2004, 3(3), 271-301.
128. Higgins, C.E.; Gross, S.S. In Nitric Oxide: Biology and Pathobiology; Ignarro, L.J., Ed., Elsevier Inc.: California, 2010; pp. 169-209.
129. Thomas, D.D.; Flores-Santana, W.; Switzer, C.H.; Wink, D.A.; Ridnour, L.A. In Nitric Oxide: Biology and Pathobiology; Ignarro, L.J., Ed., Elsevier Inc.: California, 2010; pp. 3-25.
130. Lundberg, J.O.; Weitzberg, E. In Nitric Oxide: Biology and Pathobiology; Ignarro, L.J., Ed., Elsevier Inc.: California, 2010; pp. 539-553.
131. Allen, J.D.; Giordano, T.; Kevil, C.G. Nitrite and nitric oxide metabolism in peripheral artery disease. Nitric Oxide, 2012, 26(4), 217-222.
132. Bian, K.; Ghassemi, F.; Sotolongo, A.; Siu, A.; Shauger, L.; Kots, A.; Murad, F. NOS-2 signaling and cancer therapy. IUBMB Life, 2012, 64(8), 676-683.
133. Bryan, N.S. Application of nitric oxide in drug discovery and development. Expert Opin. Drug Discov., 2011, 6(11), 1139-1154.
134. Heinrich, U.R.; Helling, K. Nitric oxide -A versatile key player in cochlear function and hearing disorders. Nitric Oxide, 2012, 27(2), 106-116.
135. Kvietys, P.R.; Granger, D.N. Role of reactive oxygen and nitrogen species in the vascular responses to inflammation. Free Radic. Biol. Med., 2012, 52(3), 556-592.
136. Loughran, P.A.; Bagci, E.Z.; Zamora, R., Vodovotz, Y., Billiar, R. In Nitric Oxide: Biology and Pathobiology; Ignarro, L.J., Ed., Elsevier Inc.: California, 2010; pp. 513-537.
137. Moya, E.A.; Alcayaga, J.; Iturriaga, R. Respir. Physiol. Neurobiol., 2012, Apr 5.
138. Napoli, C.; Crimi, E.; Williams-Ignarro, S.; de Nigris, F.; Ignarro, L.J. In Nitric Oxide: Biology and Pathobiology; Ignarro, L.J., Ed., Elsevier Inc.: California, 2010; pp. 755-772.
139. Roe, N.D.; Ren, J. Nitric oxide synthase uncoupling: A therapeutic target in cardiovascular diseases. Vascul. Pharmacol., 2012, Feb 16.
140. Terpolilli, N.A.; Moskowitz, M.A.; Plesnila, N. Nitric oxide: Considerations for the treatment of ischemic stroke. Cereb. Blood Flow. Metab., 2012, 32(7), 1332-1346.
141. Villanueva, C.; Giulivi, C. Subcellular and cellular locations of nitric oxide synthase isoforms as determinants of health and disease. Free Radic. Biol. Med., 2010, 49(3), 307-316.
142. Trujillo, M.; Alvarez, B.; Souza, JM.; Romero, N.; Castro, L., Thomson, L.; Radi, R. In Nitric Oxide: Biology and Pathobiology; Ignarro, L.J., Ed., Elsevier Inc.: California, 2010; pp. 61-102.
143. Feihl, F.; Waeber, B.; Liaudet, L. Is nitric oxide overproduction the target of choice for the management of septic shock? Pharmacol. Ther., 2001, 91(3), 179-213.
144. Cole, M.P.; Freeman B.A. In Nitric Oxide: Biology and Pathobiology; Ignarro, L.J., Ed., Elsevier Inc.: California, 2010; pp. 391-414.
145. Cauwels, A.; Brouckaert, P. Nitrite regulation of shock. Cardiovasc. Res., 2011, 89(3), 553-559.
146. Cuzzocrea, C. Effect of inhibitors of nitric oxide in animal models and future directions for therapy in inflammatory disorders Curr. Med. Chem. Anti-Inflammatory & Anti-Allergy Agents, 2004, 3(3), 261-270.
147. Cuzzocrea, S.; Riley, D.P.; Caputi, A.P.; Salvemini, D. Antioxidant therapy: A new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol. Rev., 2001, 53(1), 135-159.
148. Hauser, B.; Bracht, H.; Matejovic, M.; Radermacher, P.; Venkatesh, B. Nitric oxide synthase inhibition in sepsis? Lessons learned from large-animal studies. Anesth. Analg., 2005, 101(2), 488-498.
149. Heemskerk, S.; Masereeuw, R.; Russel, F.G.; Pickkers, P. Selective iNOS inhibition for the treatment of sepsis-induced acute kidney injury. Nat. Rev. Nephrol., 2009, 5(11), 629-640.
150. Howes, L.G.; Brillante, D.G. Expert opinion on tilarginine in the treatment of shock. Expert Opin. Investig. Drugs, 2008, 17(10), 1573-1580.
151. Stahl, W.; Matejovic, M.; Radermacher, P. Inhibition of nitric oxide synthase during sepsis: Revival because of isoform selectivity? Shock, 2010, 34(3), 321-322.
152. Sharshar, T.; Gray, F.; Lorin de la Grandmaison, G.; Hopkinson, N.S.; Ross, E.; Dorandeu, A.; Orlikowski, D.; Raphael, J.C.; Gajdos, P.; Annane, D. Apoptosis of neurons in cardiovascular autonomic centres triggered by inducible nitric oxide synthase after death from septic shock. Lancet, 2003, 362(9398), 1799-1805.
153. Hibbs, J.B.; Westenfelder, C.; Taintor, R.; Vavrin, Z.; Kablitz, C.; Baranowski, R.L.; Ward, J.H.; Menlove, R.L.; McMurry, M.P.; Kushner, J.P. Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy. J. Clin. Invest., 1992, 89(3), 867-877.
154. Gomez-Jimenez, J.; Salgado, A.; Mourelle, M.; Martin, M.C.; Segura, R.M.; Peracaula, R.; Moncada, S. L-arginine: Nitric oxide pathway in endotoxemia and human septic shock. Crit. Care Med., 1995, 23(2), 253-258.
155. de Werra, I.; Jaccard, C.; Corradin, S.B.; Chiolero, R.; Yersin, B.; Gallati, H.; Assicot, M.; Bohuon, C.; Baumgartner, J.D.; Glauser, M.P.; Heumann, D. Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: Comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit. Care Med., 1997, 25(4), 607-613.
156. Tagan, D.; Eckert, P.; Markert, M.; Feihl, F.; Schaller, M.D. Blood nitrate levels in septic and cardiogenic shock. Clin. Intensive Care, 1998, 9(2), 71-76.
157. Vallance, P.; Charles, I. Nitric oxide as an antimicrobial agent: Does NO always mean NO? Gut, 1998, 42(3), 313-314.
158. Petros, A.; Bennett, D.; Vallance, P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet, 1991, 338(8782-8783), 1557-1558.
159. Geroulanos, S.; Schilling, J.; Cakmakci, M.; Jung, H.H.; Largiader, F. Inhibition of NO synthesis in septic shock. Lancet, 1992, 339, 435.
160. Schilling, J.; Cakmakci, M.; Battig, U.; Geroulanos, S. A new approach in the treatment of hypotension in human septic shock by NG-monomethyl-L-arginine, an inhibitor of the nitric oxide synthetase. Intensive Care Med., 1993, 19(4), 227-231.
161. Lorente, J.A.; Landin, L.; De Pablo, R.; Renes, E.; Liste, D. Larginine pathway in the sepsis syndrome. Crit. Care Med., 1993, 21(9), 1287-1295.
162. Petros, A.; Lamb, G.; Leone, A.; Moncada, S.; Bennett, D.; Vallance, P. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc. Res., 1994, 28(1), 34-39.
163. Avontuur, J.A.; Biewenga, M.; Buijk, S.L.; Kanhai, K.J.; Bruining, H.A. Pulmonary hypertension and reduced cardiac output during inhibition of nitric oxide synthesis in human septic shock. Shock, 1998, 9(6), 451-454.
164. Avontuur, J.A.; Boomsma, F.; van den Meiracker, A.H.; de Jong, F.H.; Bruining, H.A. Endothelin-1 and blood pressure after inhibition of nitric oxide synthesis in human septic shock. Circulation, 1999, 99(2), 271-275.
165. Avontuur, J.A.; Buijk, S.L.; Bruining, H.A. Distribution and metabolism of N(G)-nitro-L-arginine methyl ester in patients with septic shock. Eur. J. Clin. Pharmacol., 1998, 54(8), 627-631.
166. Avontuur, J.A.; Stam, T.C.; Jongen-Lavrencic, M.; van Amsterdam, J.G.; Eggermont, A.M.; Bruining, H.A. Effect of L-NAME, an inhibitor of nitric oxide synthesis, on plasma levels of IL-6, IL-8, TNF alpha and nitrite/nitrate in human septic shock. Intensive Care Med., 1998, 24(7), 673-679.
167. Avontuur, J.A.; Tutein Nolthenius, R.P.; Buijk, S.L.; Kanhai, K.J.; Bruining, H.A. Effect of L-NAME, an inhibitor of nitric oxide synthesis, on cardiopulmonary function in human septic shock. Chest, 1998, 113(6), 1640-1646.
168. Avontuur, J.A.; Tutein Nolthenius, R.P.; van Bodegom, J.W.; Bruining, H.A. Prolonged inhibition of nitric oxide synthesis in severe septic shock: A clinical study. Crit. Care Med., 1998, 26(4), 660-667.
169. Grover, R.; Zaccardelli, D.; Colice, G.; Guntupalli, K.; Watson, D.; Vincent, J.L. An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride (546C88), in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. Crit. Care Med., 1999, 27(5), 913-922.
170. Kiehl, M.G.; Ostermann, H.; Meyer, J.; Kienast, J. Nitric oxide synthase inhibition by L-NAME in leukocytopenic patients with severe septic shock. Intensive Care Med., 1997, 23(5), 561-566.
171. Hussein, Z.; Beerahee, M.; Grover, R.; Jordan, B.; Jeffs, R.; Donaldson, J.; Zaccardelli, D.; Colice, G.; Guntupalli, K.; Watson, D.; Vincent, J.L. Pharmacokinetics of the nitric oxide synthase inhibitor L-NG-methylarginine hydrochloride in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. Clin. Pharmacol. Ther., 1999, 65(1), 1-9.
172. Lopez, A.; Lorente, J.A.; Steingrub, J.; Bakker, J.; McLuckie, A.; Willatts, S.; Brockway, M.; Anzueto, A.; Holzapfel, L.; Breen, D.; Silverman, M.S.; Takala, J.; Donaldson, J.; Arneson, C.; Grove, G.; Grossman, S.; Grover, R. Multiple-center, randomized, placebocontrolled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock. Crit. Care Med., 2004, 32(1), 21-30.
173. Watson, D.; Grover, R.; Anzueto, A.; Lorente, J.; Smithies, M.; Bellomo, R.; Guntupalli, K.; Grossman, S.; Donaldson, J.; Le Gall, J.R; Glaxo Wellcome International Septic Shock Study Group. Cardiovascular effects of the nitric oxide synthase inhibitor NGmethyl-L-arginine hydrochloride (546C88) in patients with septic shock: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit. Care Med., 2004, 32(1), 13-20.
174. Bakker, J.; Grover, R.; McLuckie, A.; Holzapfel, L.; Andersson, J.; Lodato, R.; Watson, D.; Grossman, S.; Donaldson, J.; Takala, J.; Glaxo Wellcome International Septic Shock Study Group. Administration of the nitric oxide synthase inhibitor NG-methyl-Larginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: Results of a randomized, double-blind, placebocontrolled multicenter study (study no. 144-002). Crit. Care Med., 2004, 32(1), 1-12.
175. Feleteou, M. Calcium-activated potassium channels and endothelial dysfunction: Therapeutic options? Br. J. Pharmacol., 2009, 156(4), 545-562.
176. Imig, J.D.; Simpkins, A.N.; Renic, M.; Harder, D.R. Cytochrome P450 eicosanoids and cerebral vascular function. Expert Rev. Mol. Med., 2011, 13, e7.
177. Kroetz, D.L.; Xu, F. Regulation and inhibition of arachidonic acid omega-hydroxylases and 20-HETE formation. Annu. Rev. Pharmacol. Toxicol., 2005, 45, 413-438.
178. Miyata, N.; Roman, R.J. J. Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system. Smooth Muscle Res., 2005, 41(4), 175-193.
179. Roman, R.J. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev., 2002, 82(1), 131-185.
180. Roman, R.J.; Lombard, J.H. Does 20-hydroxyeicosatetraenoic acid contribute to sex differences in cardiovascular risk by increasing oxidative stress? Hypertension, 2007, 50(1), 37-38.
181. Williams, J.M.; Murphy, S.; Burke, M.; Roman, R.J. 20-hydroxyeicosatetraeonic acid: A new target for the treatment of hypertension. J. Cardiovasc. Pharmacol., 2010, 56(4), 336-344.
182. Wu, C.C.; Schwartzman, M.L. The role of 20-HETE in androgenmediated hypertension. Prostaglandins Other Lipid Mediat., 2011, 96(1-4), 45-53.
183. Zordoky, B.N.; El-Kadi, A.O. Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. Pharmacol. Ther., 2010, 125(3), 446-463.
184. Harder, D.R.; Narayanan, J.; Gebremedhin, D. Pressure-induced myogenic tone and role of 20-HETE in mediating autoregulation of cerebral blood flow. Am. J. Physiol. Heart Circ. Physiol., 2011, 300(5), H1557-H1565.
185. Seubert, J.M.; Zeldin, D.C.; Nithipatikom, K.; Gross, G.J. Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury. Prostaglandins Other Lipid. Mediat., 2007, 82(1-4), 50-59.
186. Escalante, B.; Omata, K.; Sessa, W.; Lee, SG.; Falck, J.R.; Schwartzman, M.L. 20-hydroxyeicosatetraenoic acid is an endothelium-dependent vasoconstrictor in rabbit arteries. Eur. J. Pharmacol., 1993, 235(1), 1-7.
187. Escalante, B.; Sessa, W.C.; Falck, J.R.; Yadagiri, P.; Schwartzman, M.L. Vasoactivity of 20-hydroxyeicosatetraenoic acid is dependent on metabolism by cyclooxygenase. J. Pharmacol. Exp. Ther., 1989, 248(1), 229-232.
188. Imig, J.D.; Zou, A.P.; Stec, D.E.; Harder, D.R.; Falck, J.R.; Roman, R.J. Formation and actions of 20-hydroxyeicosatetraenoic acid in rat renal arterioles. Am. J. Physiol., 1996, 270(1 Pt 2), R217-R227.
189. Ma, Y.H.; Gebremedhin, D.; Schwartzman, M.L.; Falck, J.R.; Clark, J.E.; Masters, B.S.; Harder, D.R.; Roman, R.J. 20-Hydroxyeicosatetraenoic acid is an endogenous vasoconstrictor of canine renal arcuate arteries. Circ. Res., 1993, 72(1), 126-136.
190. Randriamboavonjy, V.; Busse, R.; Fleming I. 20-HETE-induced contraction of small coronary arteries depends on the activation of Rho-kinase. Hypertension, 2003, 41(3 Pt 2), 801-806.
191. Schwartzman, M.L.; Falck, J.R.; Yadagiri, P.; Escalante, B. Metabolism of 20-hydroxyeicosatetraenoic acid by cyclooxygenase. Formation and identification of novel endothelium-dependent vasoconstrictor metabolites. J. Biol. Chem., 1989, 264(20), 11658-11662.
192. Zou, A.P.; Fleming, J.T.; Falck, J.R.; Jacobs, E.R.; Gebremedhin, D.; Harder, D.R.; Roman, R.J. 20-HETE is an endogenous inhibitor of the large-conductance Ca(2+)-activated K+ channel in renal arterioles. Am. J. Physiol., 1996, 270(1 Pt 2), R228-R237.
193. Lange, A.; Gebremedhin, D.; Narayanan, J.; Harder, D. 20-Hydroxyeicosatetraenoic acid-induced vasoconstriction and inhibition of potassium current in cerebral vascular smooth muscle is dependent on activation of protein kinase C. J. Biol. Chem., 1997, 272(43), 27345-27352.
194. Nowicki, S.; Chen, S.L.; Aizman, O.; Cheng, X.J.; Li, D.; Nowicki, C.; Nairn, A.; Greengard, P.; Aperia, A. 20-Hydroxyeicosatetraenoic acid (20 HETE) activates protein kinase C. Role in regulation of rat renal Na+,K+-ATPase. J. Clin. Invest., 1997, 99(6), 1224-1230.
195. Obara, K.; Koide, M.; Nakayama, K. 20-Hydroxyeicosatetraenoic acid potentiates stretch-induced contraction of canine basilar artery via PKC alpha-mediated inhibition of KCa channel. Br. J. Pharmacol., 2002, 137(8), 1362-1370.
196. Sun, C.W.; Falck, J.R.; Harder, D.R.; Roman, R.J. Role of tyrosine kinase and PKC in the vasoconstrictor response to 20-HETE in renal arterioles. Hypertension, 1999, 33(1 Pt 2), 414-418.
197. Muthalif, M.M.; Benter, I.F.; Karzoun, N.; Fatima, S.; Harper, J.; Uddin, M.R.; Malik, K.U. 20-Hydroxyeicosatetraenoic acid mediates calcium/calmodulin-dependent protein kinase II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. Proc. Natl. Acad. Sci. U.S.A., 1998, 95(21), 12701-12706.
198. Muthalif, M.M.; Benter, I.F.; Khandekar, Z.; Gaber, L.; Estes, A.; Malik, S.; Parmentier, J.H.; Manne, V.; Malik, K.U. Contribution of Ras GTPase/MAP kinase and cytochrome P450 metabolites to deoxycorticosterone-salt-induced hypertension. Hypertension, 2000, 35(1 Pt 2), 457-463.
199. Muthalif, M.M.; Uddin, M.R.; Fatima, S.; Parmentier, J.H.; Khandekar, Z.; Malik, K.U. Small GTP binding protein Ras contributes to norepinephrine-induced mitogenesis of vascular smooth muscle cells. Prostaglandins Other Lipid Mediat., 2001, 65(1), 33-43.
200. Akbulut, T.; Regner, K.R.; Roman, R.J.; Avner, E.D.; Falck, J.R.; Park, F. 20-HETE activates the Raf/MEK/ERK pathway in renal epithelial cells through an EGFR-and c-Src-dependent mechanism. Am. J. Physiol. Renal Physiol., 2009, 297(3), F662-F670.
201. Sun, C.W.; Alonso-Galicia, M.; Taheri, M.R.; Falck, J.R.; Harder, D.R.; Roman, R.J. Nitric oxide-20-hydroxyeicosatetraenoic acid interaction in the regulation of K+ channel activity and vascular tone in renal arterioles. Circ. Res., 1998, 83(11), 1069-1079.
202. Gebremedhin, D.; Lange, A.R.; Narayanan, J.; Aebly, M.R.; Jacobs, E.R.; Harder, D.R. Cat cerebral arterial smooth muscle cells express cytochrome P450 4A2 enzyme and produce the vasoconstrictor 20-HETE which enhances L-type Ca2+ current. J. Physiol., 1998, 507(Pt 3), 771-81.
203. Basora, N.; Boulay, G.; Bilodeau, L.; Rousseau, E.; Payet, M.D. 20-hydroxyeicosatetraenoic acid (20-HETE) activates mouse TRPC6 channels expressed in HEK293 cells. J. Biol. Chem., 2003, 278(34), 31709-31716
204. Brayden, J.E.; Earley, S.; Nelson, M.T.; Reading, S. Transient receptor potential (TRP) channels, vascular tone and autoregulation of cerebral blood flow. Clin. Exp. Pharmacol. Physiol., 2008, 35(9), 1116-1120.
205. Carroll, M.A.; Balazy, M.; Margiotta, P.; Huang, D.D.; Falck, J.R.; McGiff, J.C. Cytochrome P-450-dependent HETEs: Profile of biological activity and stimulation by vasoactive peptides. Am. J. Physiol., 1996, 271(4 Pt 2), R863-R869.
206. Croft, K.D.; McGiff, J.C.; Sanchez-Mendoza, A.; Carroll, M.A. Angiotensin II releases 20-HETE from rat renal microvessels. Am. J. Physiol. Renal Physiol., 2000, 279(3), F544-F551.
207. Oyekan, A.; Balazy, M.; McGiff, J.C. Renal oxygenases: Differential contribution to vasoconstriction induced by ET-1 and ANG II. Am. J. Physiol., 1997, 273(1 Pt 2), R293-R300.
208. Oyekan, A.O.; McGiff, J.C. Cytochrome P-450-derived eicosanoids participate in the renal functional effects of ET-1 in the anesthetized rat. Am. J. Physiol., 1998, 274(1 Pt 2), R52-R61.
209. Cambj-Sapunar, L.; Yu, M.; Harder, D.R.; Roman, R.J. Contribution of 5-hydroxytryptamine1B receptors and 20-hydroxyeiscosatetraenoic acid to fall in cerebral blood flow after subarachnoid hemorrhage. Stroke, 2003, 34(5), 1269-1275.
210. Alonso-Galicia, M.; Drummond, H.A.; Reddy, K.K.; Falck, J.R.; Roman, R.J. Inhibition of 20-HETE production contributes to the vascular responses to nitric oxide. Hypertension, 1997, 29(1 Pt 2), 320-325.
211. Alonso-Galicia, M.; Hudetz, A.G.; Shen, H.; Harder, D.R.; Roman, R.J. Contribution of 20-HETE to vasodilator actions of nitric oxide in the cerebral microcirculation. Stroke, 1999, 30(12), 2727-2734.
212. Lopez, B.; Moreno, C.; Salom, M.G.; Roman, R.J.; Fenoy, F.J. Role of guanylyl cyclase and cytochrome P-450 on renal response to nitric oxide. Am. J. Physiol. Renal Physiol., 2001, 281(3), F420-F427.
213. Oyekan, A.O.; McGiff, J.C. Functional response of the rat kidney to inhibition of nitric oxide synthesis: Role of cytochrome p450-derived arachidonate metabolites. Br. J. Pharmacol., 1998, 125(5), 1065-1073.
214. Botros, F.T.; Laniado-Schwartzman, M.; Abraham, N.G. Regulation of cyclooxygenase-and cytochrome p450-derived eicosanoids by heme oxygenase in the rat kidney. Hypertension; 2002, 39(2 Pt 2), 639-644.
215. Coceani, F.; Kelsey, L.; Seidlitz, E.; Korzekwa, K. Inhibition of the contraction of the ductus arteriosus to oxygen by 1-aminobenzotriazole, a mechanism-based inactivator of cytochrome P450. Br. J. Pharmacol., 1996, 117(7), 1586-1592.
216. Hoagland, K.M.; Maier, K.G.; Roman, R.J. Contributions of 20-HETE to the antihypertensive effects of Tempol in Dahl saltsensitive rats. Hypertension, 2003, 41(3), 697-702.
217. Alonso-Galicia, M.; Sun, C.W.; Falck, J.R.; Harder, D.R.; Roman, R.J. Contribution of 20-HETE to the vasodilator actions of nitric oxide in renal arteries. Am. J. Physiol., 1998, 275(3 Pt 2), F370-F378.
218. Cheng, J.; Ou, J.S.; Singh, H.; Falck, J.R.; Narsimhaswamy, D.; Pritchard, K.A.Jr.; Schwartzman, M.L. 20-hydroxyeicosatetraenoic acid causes endothelial dysfunction via eNOS uncoupling. Am. J. Physiol. Heart Circ. Physiol., 2008, 294(2), H1018-H1026.
219. Cheng, J.; Wu, C.C.; Gotlinger, K.H.; Zhang, F.; Falck, J.R.; Narsimhaswamy, D.; Schwartzman, M.L. 20-hydroxy-5,8,11,14-eicosatetraenoic acid mediates endothelial dysfunction via IkappaB kinase-dependent endothelial nitric-oxide synthase uncoupling. J. Pharmacol. Exp. Ther., 2010, 332(1), 57-65.
220. Wang, J.S.; Singh, H.; Zhang, F.; Ishizuka, T.; Deng, H.; Kemp, R.; Wolin, M.S.; Hintze, T.H.; Abraham, N.G.; Nasjletti, A.; Laniado-Schwartzman, M. Endothelial dysfunction and hypertension in rats transduced with CYP4A2 adenovirus. Circ. Res., 2006, 98(7), 962-969.
221. Carroll, M.A.; Garcia, M.P.; Falck, J.R.; McGiff, J.C. Cyclooxygenase dependency of the renovascular actions of cytochrome P450-derived arachidonate metabolites. J. Pharmacol. Exp. Ther., 1992, 260(1), 104-109.
222. Carroll, M.A.; Capparelli, M.F.; Doumand, A.B.; Cheng, M.K.; Jiang, H.; McGiff, J.C. Renal vasoactive eicosanoids: Interactions between cytochrome P450 and cyclooxygenase metabolites during salt depletion. Am. J. Hypertens., 2001, 14, 159A.
223. Fang, X.; Faraci, F.M.; Kaduce, T.L.; Harmon, S.; Modrick, M.L.; Hu, S.; Moore, S.A., Falck, J.R., Weintraub, N.L., Spector, A.A. 20-Hydroxyeicosatetraenoic acid is a potent dilator of mouse basilar artery: Role of cyclooxygenase. Am. J. Physiol. Heart Circ. Physiol., 2006, 291(5), H2301-F2307.
224. Pratt, P.F.; Falck, J.R.; Reddy, K.M.; Kurian, J.B.; Campbell, W.B. 20-HETE relaxes bovine coronary arteries through the release of prostacyclin. Hypertension, 1998, 31(1 Pt 2), 237-241.
225. Yu, M.; McAndrew, R.P.; Al-Saghir, R.; Maier, K.G.; Medhora, M.; Roman, R.J.; Jacobs, E.R. Nitric oxide contributes to 20-HETE-induced relaxation of pulmonary arteries. J. Appl. Physiol., 2002, 93(4), 1391-1399.
226. Oyekan, A.O.; McAward, K.; Conetta, J.; Rosenfeld, L.; McGiff, J.C. Endothelin-1 and CYP450 arachidonate metabolites interact to promote tissue injury in DOCA-salt hypertension. Am. J. Physiol., 1999, 276(3 Pt 2), R766-R775.
227. Wang, M.H.; Wang, J.; Chang, H.H.; Zand, B.A.; Jiang, M.; Nasjletti, A.; Laniado-Schwartzman, M. Regulation of renal CYP4A expression and 20-HETE synthesis by nitric oxide in pregnant rats. Am. J. Physiol., 2003, 285(2), F295-F302.
228. Yu, M.; Lopez, B.; Dos Santos, E.A.; Falck, J.R.; Roman, R.J. Effects of 20-HETE on Na+ transport and Na+-K+-ATPase activity in the thick ascending loop of Henle. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2007, 292(6), R2400-R2405.
229. Oyekan, A.O.; Youseff, T.; Fulton, D.; Quilley, J.; McGiff, J.C. Renal cytochrome P450 omega-hydroxylase and epoxygenase activity are differentially modified by nitric oxide and sodium chloride. J. Clin. Invest., 1999, 104(8), 1131-1137.
230. Escalante, B.A.; McGiff, J.C.; Oyekan, A.O. Role of cytochrome P-450 arachidonate metabolites in endothelin signaling in rat proximal tubule. Am. J. Physiol. Renal Physiol., 2002, 282(1), F144-F150.
231. Sewer, M.B.; Koop, D.R.; Morgan, E.T. Differential inductive and suppressive effects of endotoxin and particulate irritants on hepatic and renal cytochrome P-450 expression. J. Pharmacol. Exp. Ther., 1997, 280(3), 1445-1454.
232. Mitchell, S.R.; Sewer, M.B.; Kardar, S.S.; Morgan, E.T. Characterization of CYP4A induction in rat liver by inflammatory stimuli: Dependence on sex, strain, and inflammation-evoked hypophagia. Drug Metab. Dispos., 2001, 29(1), 17-22.
233. Renton, K.W.; Nicholson, T.E. Hepatic and central nervous system cytochrome P450 are down-regulated during lipopolysaccharideevoked localized inflammation in brain. J. Pharmacol. Exp. Ther., 2000, 294(2), 524-530.
234. Sewer, M.B.; Koop, D.R.; Morgan, E.T. Endotoxemia in rats is associated with induction of the P4504A subfamily and suppression of several other forms of cytochrome P450. Drug Metab. Dispos., 1996, 24(4), 401-407.
235. Sewer, M.B.; Morgan, E.T. Down-regulation of the expression of three major rat liver cytochrome P450S by endotoxin in vivo occurs independently of nitric oxide production. J. Pharmacol. Exp. Ther., 1998, 287(1), 352-358.
236. Takemura, S.; Minamiyama, Y.; Imaoka, S.; Funae, Y.; Hirohashi, K.; Inoue, M.; Kinoshita, H. Hepatic cytochrome P450 is directly inactivated by nitric oxide, not by inflammatory cytokines, in the early phase of endotoxemia. J. Hepatol., 1999, 30(6), 1035-1044.
237. Khatsenko, O.G.; Kikkawa, Y.J. Nitric oxide differentially affects constitutive cytochrome P450 isoforms in rat liver. Pharmacol. Exp. Ther., 1997, 280(3), 1463-1470.
238. Khatsenko, O.G.; Gross, S.S.; Boobis, A.B. Evidence for nitric oxide participation in down-regulation of CYP2B1/2 gene expression at the pretranslational level. Toxicol. Lett., 1997, 90(2-3), 207-216.
239. Morgan, E.T.; Li-Masters, T., Cheng, P.Y. Mechanisms of cytochrome P450 regulation by inflammatory mediators. Toxicology, 2002, 181-182, 207-210.
240. Müller, C.B.; Scierka, A.; Stiller, R.L.; Kim, Y.M.; Cook, R.D.; Lancaster, J.R.; Buffington, C.W. Nitric oxide mediates hepatic cytochrome P450 dysfunction induced by endotoxin. Anesthesiology, 1996, 84(6), 1435-1442.
241. Tunctan, B.; Yaghini, F.A.; Estes, A.; Malik, K.U. Inhibition by nitric oxide and cyclooxygenase of cytochrome P450 4A expression and activity contributes to endotoxin-induced hypotension in rats. Nitric Oxide: Biol. Chem., 2006, 14(1), 51-57.
242. Buharalioglu, CK.; Korkmaz, B.; Cuez, T.; Sahan-Firat, S.; Sari, A.N.; Malik, K.U.; Tunctan, B. Piroxicam reverses endotoxininduced hypotension in rats: Contribution of vasoactive eicosanoids and nitric oxide. Basic Clin. Pharmacol. Toxicol., 2011, 109(3), 186-194.
243. Tunctan, B.; Korkmaz, B.; Cuez, T.; Sari, A.N.; Kacan, M.; Gilik, D.; Buharalioglu, C.K.; Sahan-Firat, S.; Schunck, W.H.; Serin, M.S.; Falck, J.R.; Malik, K.U. Contribution of iNOS, COX-2 and CYP4A1 to the protective effect of a synthetic analog of 20-HETE, 5,14-HEDGE, against endotoxin-induced hypotension and mortality in experimental model of septic shock in rats and mice. Inflam. Res., 2011, 60(Suppl 1), S55.
244. Tunctan, B.; Sari, A.N.; Kacan, M.; Unsal, D.; Buharalioglu, C.K.; Sahan-Firat, S.; Korkmaz, B.; Falck, J.; Malik, K.U. NS-398 reverses hypotension in endotoxemic rats: Contribution of eicosanoids, NO, and peroxynitrite. Prostaglandins Other Lipid Mediat., 2012, Sep 5.
245. Cuez, T.; Korkmaz, B.; Buharalioglu, C.K.; Sahan-Firat, S.; Falck, J.; Malik, K.U.; Tunctan, B. A synthetic analogue of 20-HETE, 5,14-HEDGE, reverses endotoxin-induced hypotension via increased 20-HETE levels associated with decreased iNOS protein expression and vasodilator prostanoid production in rats. Basic Clin. Pharmacol. Toxicol., 2010, 106(5), 378-388.
246. Korkmaz, B.; Buharalioglu, K.; Sahan-Firat, S.; Cuez, T.; Demiryurek, T.A.; Tunctan, B. Activation of MEK1/ERK1/2/ iNOS/sGC/PKG pathway associated with peroxinitrite formation contributes to hypotension and vascular hyporeactivity in endotoxemic rats. Nitric Oxide: Biol. Chem., 2011, 24(3), 160-172.
247. Tunctan, B.; Korkmaz, B.; Yildirim, H.; Tamer, L.; Atik, U.; Buharalioglu, C.K. Increased production of nitric oxide contributes to renal oxidative stress in endotoxemic rat. Am. J. Infect. Dis., 2005, 1(2), 111-115.
248. Tunctan, B.; Korkmaz, B.; Yildirim, H.; Tamer, L.; Atik, U.; Buharalioglu, C.K. Reversal of endotoxin-induced hypotension by inhibition of inducible nitric oxide synthase activity is associated with improved oxidative status in rat heart, aorta and mesenteric artery. Turkish J. Med. Sci., 2006, 36(2):71-80.
249. Tunctan, B.; Korkmaz, B.; Dogruer, Z.N.; Tamer, L.; Atik, U. Inhibition of extracellular signal-regulated kinase (ERK1/2) activity reverses endotoxin-induced hypotension via decreased nitric oxide production in rats. Pharmacol. Res., 2007, 56(1), 56-64.
250. Tunctan, B.; Yaghini, F.A.; Estes, A.; Malik, K.U. Prostaglandins inhibit cytochrome P450 4A activity and contribute to endotoxininduced hypotension in rats via nitric oxide production. Arch. Pharm. Res., 2008, 31(7), 856-865.
251. Tunctan, B.; Korkmaz, B.; Buharalioglu, CK.; Sahan Firat, S.; Anjaiah, S.; Falck, J.; Roman, R.J.; Malik, K.U. A 20-HETE agonist, N-[20-hydroxyeicosa-5(Z),14(Z)-dienoyl]glycine, opposes the fall in blood pressure and vascular reactivity in endotoxintreated rats. Shock, 2008, 30(3), 329-335.
252. Tunctan, B.; Korkmaz, B.; Cuez, T.; Buharalioglu, C.K.; Sahan-Firat, S.; Falck, J.; Malik, K.U. Contribution of vasoactive eicosanoids and nitric oxide production to the effect of selective cyclooxygenase-2 inhibitor, NS-398, on endotoxin-induced hypotension in rats. Basic Clin. Pharmacol. Toxicol., 2010, 107(5), 877-882.
253. Sahan-Firat, S.; Canacankatan, N.; Korkmaz, B.; Yildirim, H.; Tamer, L.; Buharalioglu, C.K.; Sari, A.N.; Kacan, M.; Unsal, D.; Tunctan, B. Increased production of nitric oxide mediates selective organ-specific effects of endotoxin on oxidative stress. Antiinflamm. Antiallergy Agents Med. Chem., 2012, Jul 19.
254. Blantz, R.C.; Munger, K. Role of nitric oxide in inflammatory conditions. Nephron, 2002, 90(4), 373-378.
255. Cheng, H.F.; Harris, R.C. Does cyclooxygenase-2 affect blood pressure? Curr. Hypertens. Rep., 2003, 5(1), 87-92.
256. Murakami, M.; Naraba, H.; Tanioka, T.; Semmyo, N.; Nakatani, Y.; Kojima, F.; Ikeda, T.; Fueki, M.; Ueno, A.; Oh-ishi, S.; Kudo, I. Regulation of prostaglandin E2 biosynthesis by inducible membraneassociated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J. Biol. Chem., 2000, 275(42), 32783-32792.
257. Okita, R. Effect of acetylsalicylic acid on fatty acid omegahydroxylation in rat liver. Ped. Res., 1986, 20(12), 1221-1224.
258. Rekka, E.; Ayalogu, E.O.; Lewis, D.F.V.; Gibson, G.G.; Ioannides, C. Induction of hepatic microsomal CYP4A activity and of peroxisomal beta-oxidation by two non-steroidal anti-inflammatory drugs. Arch. Toxicol., 1994, 68(2), 73-78.
259. Anwar-Mohamed, A.; Zordoky, B.N.; Aboutabl, M.E.; El-Kadi, A.O. Alteration of cardiac cytochrome P450-mediated arachidonic acid metabolism in response to lipopolysaccharide-induced acute systemic inflammation. Pharmacol. Res., 2010, 61(5), 410-418.
260. Theken, K.N.; Deng, Y.; Kannon, M.A.; Miller, T.M.; Poloyac, S.M.; Lee, C.R. Activation of the acute inflammatory response alters cytochrome P450 expression and eicosanoid metabolism. Drug. Metab. Dispos., 2011, 39(1), 22-29.
261. Cuzzocrea, S.; Salvemini, D. Molecular mechanisms involved in the reciprocal regulation of cyclooxygenase and nitric oxide synthase enzymes. Kidney Int., 2007, 71(4); 290-297.
262. Kompanowska-Jezierska, E.; Kuczeriszka, M. Cytochrome P-450 metabolites in renal circulation and excretion-interaction with the nitric oxide (NO) system. J. Physiol. Pharmacol., 2008, 59(Suppl 9), 137-149.
263. Mariotto, S.; Suzuki, Y.; Persichini, T.; Colasanti, M.; Suzuki, H.; Cantoni, O. Cross-talk between NO and arachidonic acid in inflammation. Curr. Med. Chem., 2007, 14(18), 1940-1944.
264. Mollace, V.; Muscoli, C.; Masini, E.; Cuzzocrea, S.; Salvemini, D. Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol. Rev., 2005, 57(2), 217-252.